



RESI REDEFINING
EARLY STAGE
INVESTMENTS

RESI Boston 2024 Conference Brochure

- September 25: The Westin Copley Place
(10 Huntington Ave, Boston, Ma 02116)
- September 26-27: Virtual Partnering Only





Face to Face Partnering



Investor Panel & Workshop



Pitch Session




Virtual Partnering


We expect **250+ early-stage life science innovators** and **250+ early-stage life science investors** to participate in RESI Europe 2024.

| | |
|------------------|-----|
| Tech Hub | 47% |
| Service Provider | 42% |
| Non-Profit | 10% |
| Others | 1% |

| | |
|------------------------|-----|
| Venture Capital | 44% |
| Angel & Family Office | 17% |
| Large Pharma & Biotech | 15% |
| Corporate VC | 12% |
| Endowments/Foundation | 8% |
| Private Equity | 4% |



Discover New Life Science Companies Seeking Partnership



Partnering Overview Partnering is one of the most valuable facets of RESI conferences. The partnering platform is designed to match attendees based on sector, indication, phase of development, etc. (see below to see criteria), eliminating the question, “Is this a good fit for my needs?” Fundraising companies match with a diverse pool of investors who fit both development stage and product set. Investors and strategic partners can explore the latest innovation in a format that easily connects them with products they are most interested in. Sponsors, exhibitors, and providers also can review attendee profiles to find the best fit for their services.

How Does it Work? Partnering providing time to upload personal schedules and company profiles, as well as review and request meetings with attendees using the filters based on which attendees you are most interested in meeting.


LSN hosts free workshops to review platform function and provide tips for anyone who is new or inexperienced with partnering events. Click the video to view a partnering tutorial.



LIFE SCIENCE NATION
Connecting Products, Services & Capital

Digital RESI Partnering Tutorial

Greg Mannix
Chief Conference Officer, VP of Global Business Development
g.mannix@lifesciencenation.com



Home Search Sessions Messages Schedule Account

Start searching... Search

Print 1 2 3 4 5 6 7 8 9 10 237 results found Order alphabetically

Groups

- All
- Biotech/Medtech/Diagnostics/HIT
- Investors
- Non-Profits
- Other
- Service Providers/Consultants
- Tech Hubs

1984 Ventures

1984 Ventures is a venture capital firm based in San Francisco, CA. The firm focuses on making investments in early-seed rounds, primarily invests in biotech and medtech startups, and is interested in solving worldwide problems. Within life sciences/healthcare, the firm is most interested in opportunities in diagnostics and therapeutics. The firm is focused on USA-based opportunities.

Premier Mandate (for Premier Plus Delegates only)
<http://resipremium.meeting-mojo.com/search?id=314099>

Investor Type: **Venture Capital**

Main Sector:

- Biotech Therapeutics
- Biotechnology Other
- Biotechnology R&D Services
- Diagnostics
- Healthcare IT
- Medical Technology
- Supplier & Engineering

Therapeutic Product Development Phase:

- NDA
- Phase I
- Phase II
- Phase III
- Pre-Clinical

Medtech/Diagnostic Development Phase:

- Clinical
- In Development
- On the Market

Orphan Interest? No

Capital Structure Preference:

- Equity

Investment Stage:

- Growth
- Seed
- Venture

Year Founded: 2017

Farzad Soleimani
Healthcare Partner

3E Bioventures

3E Bioventures Capital is a healthcare focused venture investment firm based in Alto, CA. The firm has invested in therapeutics in a wide range of disorders. These investments covered a wide range of modalities, additionally invested in medical device and imaging technologies. Investments were made during pre-clinical trials, while device investments were made in research tools and animal medicine as well. The firm has invested over \$10MM and were made in venture rounds.

Premier Mandate (for Premier Plus Delegates only)
<http://resipremium.meeting-mojo.com/search?id=314094>

Send message Bookmark

The **Standard Partnering Profile** provides filterable information about each investor's sector(s), indications(s) and phase(s) of development they seek. Attendees reviewing a standard profile can judge if they are a fit for their product offerings. Standard profiles contain:

- Allocation Information
- Investor Type
- Main Sector
- Indications
- Phase of Development
- Orphan Interest
- Capital Structure Preference
- Investment Stage
- Attending Investors
- "Book Meetings" Option

A **Premier Partnering Profile** provides exclusive access to full investor mandates, imported from LSN's database with 5,000+ profiles, including personal contact information for each investor. This information is gathered by LSN's investor research team, based on annual conversations and updates provided through one-on-one updates. **Attendees can upgrade their standard profile to premier for an additional \$500.**

Premier Partnering Only Content

- Access to Investor Mandates
- Direct Contact Email
- Sectors and Sub-Sectors of Interest
- Company & Management Team Requirements

6 Dimensions Capital

Allocation Information

6 Dimensions Capital is a healthcare-focused venture capital firm formed in 2017 through the merger of Frontline BioVentures and WuXi Healthcare Ventures. Frontline BioVentures manages 2 funds, a RMB denominated fund and a parallel USD fund. WuXi Healthcare Ventures manages its \$250 million Fund II, with WuXi PharmaTech being the anchor. The firm generally seeks to make equity investments into emerging life science companies in seed and venture stages; however, the fund also considers commercial-stage companies, depending on the opportunity. The investment size of the USD fund ranges from \$5 - \$25 million. For the RMB fund, typical investment size is RMB 30- RMB150 million. The firm currently focuses on China-based companies or overseas businesses with a China angle.

Sectors and Subsectors of Interest

6 Dimensions Capital is looking for new investment opportunities across a wide spectrum of life science sectors, including Therapeutics, Diagnostics, Biotech R&D Services, Medical Technology and Healthcare IT. The firm is agnostic to disease indications but is most interested in areas with large market potential, including Diabetes, Cardiovascular, Musculoskeletal System and Connective Tissue, Diseases of the Eye and Oncology. Rare diseases are generally less of interest. The firm is open to invest in both small molecules and biologics, and it looks for all classes of devices. The funds are most interested in companies in preclinical and early-clinical stage, but they are open to companies in late-clinical and growth stage, on a case-by-case basis.

Company and Management Team Requirements

6 Dimensions Capital will only invest in private companies. The firm is looking to be an active investor, sometimes taking a board seat post-investment.

Investor Type

Venture Capital

Main Sector

- Biotech Therapeutics
- Biotechnology Other
- Biotechnology R&D Services
- Diagnostics
- Healthcare IT
- Medical Technology
- Supplier & Engineering

Indications

- Blood Diseases/Immune Disorders
- Cardiovascular
- Cond. Orig. in the Prenatal Period
- Congen. Deform. & Chrom. Defects
- Digestive System
- Diseases of the Ear
- Diseases of the Eye
- Diseases of the Nervous System
- Endocrine/Nutri/Metabolic Dis.
- Ext. Causes of Morbidity & Mortality
- Genitourinary System
- Infectious and Parasitic Diseases
- Mental and Behavioral Disorders
- Musculoskeletal Sys. Connect. Tiss.
- Neoplasms/Cancer/Oncology
- Other
- Pain and Inflammation
- Physical Injury/Poisoning
- Pregnancy/Childbirth & Puerperium
- Respiratory
- Skin and Subcutaneous Tissue

Therapeutic Product Development Phase

- NDA
- Phase I
- Phase II
- Phase III
- Pre-Clinical

Medtech/Diagnostic Development Phase

- Clinical
- In Development
- On the Market

Orphan Interest?

No

Capital Structure Preference

- Equity

Investment Stage

- Growth
- Seed
- Venture

Year Founded

2017

Direct Contact Email

Executive Director
Contact Email

Click To Request a Meeting

<https://digital-resi-sept.meeting-mojo.com/search?id=314001>

The **Innovator's Pitch Challenge** (IPC) is an opportunity for early-stage companies to gain additional exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session. Participating companies pay \$3,495 for the pitch package, which includes a 3-day standard ticket.

(Pitch package does not include poster printing.)

Participants receive:


- A 4-min live pitching slot with 9-min investor Q&A
- A Dedicated poster space for company materials onsite
- Media promotion on the LSN newsletter and social media

The live Q&A sessions are available to the entire conference and include a curated panel of investor judges. All attendees are encouraged to vote for the most innovative company.

The top 3 winners will be announced on the conference website and in the Next Phase Newsletter after the conference. Winners receive free registrations to future partnering events.

Apply to Pitch

Application Deadline is August 14



IPC Posters



Live Pitch & Investor Q&A



IPC Winner Announcement



Social Media Promotion

"I'm really happy to have participated in RESI and the IPC format. The investors were predominantly stage-and sector-appropriate for a biotech start up... The IPC format was helpful in that we were able to post a short pitch online for on-demand viewing as well as having a 'live' discussion. Several of the panelists met with me after the panel, and I've been contacted by one investor (so far) outside the meeting after they'd seen the video pitch. I'm happy to recommend this meeting and the IPC format for early-stage biotech companies-I think this was money and time well spent for us."

- Ross Breckenridge, CEO, Arjuna Therapeutics

Panels

Panels are live onsite and made available for future viewing via the live agenda. These 50-minute discussions feature panelists and a moderator made up of active investors, strategic partners, and key industry leaders, with a diverse range of topics focused on the early-stage life science ecosystem.

In order to provide maximum value, LSN goes beyond partnering with expert panels and industry workshops – each designed with the early-stage player in mind – and available to help sponsors reach their goals.

Workshops

Workshops are designed to educate leaders of fundraising companies on elements of the early-stage landscape often overlooked, which can include patents, recruitment, intellectual property, insurance, financial management, and so much more.



RESI helps companies gain unprecedented visibility into the early-stage life science community, and also leverage **Life Science Nation** (LSN)'s close-knit network of key decision-makers to make promising connections with future clients.

Service providers are an important asset to the LSN community, and service provider registration increases deal pipeline and access to investor portfolios, as well as introduce early-stage companies developing the hottest new technologies in drugs, devices, diagnostics and digital health to the many opportunities available through service providers.

[Contact us to learn more!](#)




[Click to View Sponsorship Brochure](#)

Past Partners



STARTUP



Unable to travel? Check out the 2-day Virtual option

This registration option allows you partnering for the 2 virtual days and access to the recordings of the live sessions

SERVICE PROVIDER

Service provider looking to meet with potential customers?

Service Provider Registration

This registration option is for service providers looking to meet with early-stage CEO's and present their services to potential future clients.

Exhibitor Registration

This registration option is also for services providers looking to meet with potential future clients and grants you an exhibit table to gain additional exposure.

Unable to travel? Check out the 2-day Virtual option

This registration option allows you partnering for the 2 virtual days and access to the recordings of the live sessions

| REGISTER NOW | Standard 3-day (Sept. 25 - 27) | Virtual 2-day (Sept. 26 - 27) | In-person 1-day (Sept. 25) | Audience Access Pass (Sept. 25) |
|------------------------------------|---|--|--|---|
| Startup | Super Early Bird: \$1,495 Early Bird: \$1,695 Standard: \$1,995 | Super Early Bird: \$595 Early Bird: \$695 Standard: \$895 | Super Early Bird: \$1,195 Early Bird: \$1,395 Standard: \$1,695 | <p>\$595 (Fixed)</p> <p>This low-cost audience pass will give you access to all the RESI live sessions through panels, IPC live Q&A and workshops on September 25 No partnering access.</p> |
| Service Provider | Super Early Bird: \$1,995 Early Bird: \$2,195 Standard: \$2,495 | Super Early Bird: \$1,195 Early Bird: \$1,295 Standard: \$1,495 | Super Early Bird: \$1,695 Early Bird: \$1,895 Standard: \$2,195 | |
| Exhibitor | <p>Super Early Bird: \$3,990 Early Bird: \$4,390 Standard: \$4,990</p> <p>View Sponsorship Brochure</p> <p>Includes Two 3-Day Standard Tickets and an Exhibition Table</p> | | | |
| Tech Hub & Constituents | \$1,495 (fixed) | \$595 (fixed) | \$1,195 (fixed) | |
| Investor | Complimentary – Learn more about terms applied. | | | |

- Super Early Bird Rates: **Until July 5, 2024**
- Early Bird Rates: **July 6 – August 2, 2024**
- Standard Rates: **After August 2, 2024**

Want to learn more? We are available to answer questions and share additional details to help you meet your partnership goals! RESI@lifesciencenation.com